GlassScriptPhysician profile
Maher Chehab
NPI 1699294728
$4,934.67
in general payments reported to CMS, 2019-2025
26 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $795 · 2022: $1,231 · 2023: $1,538 · 2024: $1,076 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.74 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.08 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $735.14 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $422.55 | 2022-2025 | Spravato, Invega Sustenna, Invega |
| Axsome Therapeutics, INC. | $266.14 | 2023-2025 | Auvelity |
| Corium, LLC | $260.06 | 2021-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $259.47 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $238.32 | 2021-2024 | Rexulti |
| Alkermes, INC. | $225.89 | 2022-2023 | Aristada, Aristada Initio, Lybalvi |
| Sunovion Pharmaceuticals INC. | $224.23 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $219.90 | 2022-2024 | Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.93 | 2021-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $168.59 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $142.76 | 2021-2024 | Trintellix |
| Bausch Health US, LLC | $133.58 | 2021-2024 | Aplenzin |
| Vanda Pharmaceuticals INC. | $130.97 | 2021-2024 | Fanapt, Hetlioz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $87.71 | 2021-2024 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $53.38 | 2022-2023 | Ingrezza |
| Eisai INC. | $42.17 | 2022 | |
| Jazz Pharmaceuticals INC. | $33.31 | 2021-2022 | |
| Sage Therapeutics, LLC | $26.58 | 2021 | |
| Tempus Ai, INC | $25.00 | 2025 | Tempus Pixel |
| Collegium Pharmaceutical, INC. | $24.01 | 2025 | Jornay Pm |
| Indivior INC. | $21.07 | 2024 | Perseris |
| Novo Nordisk INC | $19.75 | 2023 | Wegovy |
| Noven Therapeutics, LLC | $17.59 | 2023 | Xelstrym |
| Almatica Pharma LLC | $14.49 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Chehab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.